

Verdict received in US dispute involving Gambro

Stockholm, Sweden, April 23, 2003 – Gambro AB (Stockholmsbörsen: GAMBaST, GAMBbST), a leading international medical technology and healthcare company, today announced that a jury verdict was received in a lawsuit that had been pending in a United States court in Florida for approximately six years. As outlined in the Gambro Annual Report 2002 (Note 31), the lawsuit, Ginsburg et al. vs. Gambro et al., relates to a 1995 tender offer to all public stockholders in REN Corporation US (REN) pursuant to which Gambro, Inc. acquired all of the remaining outstanding shares of REN for a total consideration of nearly MUSD 190. In 1997 a former REN stockholder sued Gambro making various allegations regarding the transaction.

Trial began March 17, 2003 and the verdict was received on April 16, 2003. The jury awarded approximately MUSD 3.7 in compensatory damages to the plaintiffs even though the plaintiffs had, during the trial, requested significantly higher compensatory damages, and would have requested punitive damages of several times the compensatory damages. The jury declined to award any punitive damages. Based on the level of compensatory damages awarded, pre-judgment interest in the amount of approximately MUSD 2 is expected to be added. Gambro has filed a motion to reduce the amount of compensatory damages and accompanying interest on several legal grounds. When a final judgment is rendered, by the judge, certain attorneys fees and costs are expected to be added in amounts that have not yet been established. Once the judgment is entered both parties will have a limited period of time to appeal the verdict.

Gambro will accrue for the MUSD 3.7 as an additional acquisition cost in the March 31, 2003 balance sheet (increase of goodwill and accruals), but, pending the final judgment no interest expense or legal fees subsequent to March 31 will be included in the first quarter income statement. These amounts are expected to be established before the end of the second quarter and will be reported accordingly.

For further information please contact:

Bengt Modéer, Senior Vice President, Corporate Communications, tel. +46-8-613 65 33,
+46-70-513 65 33

Pia Irell, Investor Relations Director, Corporate Finance, tel. +46-8-613 65 91, +46-70-513 65 91

Kevin Smith, President Gambro Inc., Investor Relations US, tel. +1-303 231 4750

Gambro is a global medical technology and healthcare company with leading positions in renal care - services and products - and blood component technology. Gambro Healthcare is one of the leading providers of kidney dialysis services in the world with more than 53,500 patients in 693 clinics worldwide. Gambro Renal Products comprises dialyzers, dialysis machines, blood lines and dialysis concentrates. Gambro BCT is the market leader in separation and handling of blood components. The group, with 2002 revenues of approximately SEK 27.6 billion (USD 2.7 billion), has 20,900 employees in some 40 countries.

Gambro AB

A public company (publ)
Reg no. 556041-8005
Jakobsgatan 6, PO Box 7373
SE-103 91 Stockholm
Sweden
Tel +46 8-613 65 00
Fax +46 8-611 28 30
info@gambro.com
www.gambro.com